BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....
BC Innovations | Oct 10, 2019
Distillery Therapeutics

Inhibiting translation initiation for androgen receptor-deficient prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Disrupting the eIF4F translation initiation complex formation could treat androgen receptor-deficient prostate cancers. Low expression of the translation inhibitor e1F4EBP1, which when hypophosphorylated prevents eIF4F complex formation, correlated with...
BC Week In Review | Oct 19, 2018
Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
BC Extra | Oct 16, 2018
Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
BioCentury | Jun 12, 2018
Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and...
BC Week In Review | Apr 27, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
BioCentury | Apr 27, 2018
Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and...
BC Extra | Apr 24, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
BC Innovations | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Eukaryotic translation initiation factor 4E binding protein 1 (eIF4EBP1)

Endocrine/metabolic disease INDICATION: Obesity Mouse studies suggest promoting eIF4EBP1 expression could help treat obesity. In mice fed a high-fat diet, transgenic expression of human eIF4EBP1 decreased body weight, serum levels of leptin, triglycerides and IL-6,...
BC Innovations | Mar 24, 2016
Strategy

Combo platter

In the last few years, Incyte Corp. has changed its strategy to incorporate combination options into the design and selection of its NCEs from the start. The company has developed an approach to target independent...
Items per page:
1 - 10 of 17